Key takeaways
- Aromatase makes estradiol from testosterone inside bone, brain and vessel wall, so suppressing it lowers what those tissues can make for themselves.
- Estradiol carries most of the sex-hormone workload in male bone, and is required for normal libido and erectile function.
- Roughly 20-40 pg/mL on a sensitive assay is a target, not a ceiling to undercut; standard immunoassays are unreliable at male levels.
- Most estradiol problems on therapy are dose and injection-frequency problems in disguise.
A man starts testosterone therapy, feels good for a month, then reads that estrogen causes bloating and breast tissue and asks for something to block it. Six weeks later his joints ache and his libido has gone despite an excellent testosterone number. This is one of the most common self-inflicted problems in male hormone care, and it comes from a single wrong premise: that estradiol in men is a side effect rather than a hormone men need.
Where a man's estradiol comes from
Men do not have a separate manufacturing route for estradiol. They make it out of testosterone using an enzyme called aromatase, and that conversion is not a leak in the system — it is part of the design. Aromatase is expressed in adipose tissue, bone, brain, blood vessel walls and the testes, which means a good deal of estradiol is produced locally, inside the tissue that uses it, rather than delivered by the bloodstream.
That local production is the part most people miss. A blood estradiol level is a partial readout of what bone and brain are actually exposed to, because those tissues make their own supply from circulating testosterone. Suppress aromatase systemically and you do not just lower a number in serum; you lower what those tissues can make for themselves.
The clearest demonstration comes from the rare men born with aromatase deficiency. Despite normal or high testosterone they present with unfused growth plates, severe osteopenia and a poor metabolic profile (Simpson et al., Mol Cell Endocrinol 1998) — an experiment nature runs occasionally, and one that settles the question of whether estradiol is optional in men. The aromatase enzyme in detail covers the biology further.
What estradiol is doing while you are not thinking about it
- Bone. The dominant sex-hormone regulator of bone resorption in men, not testosterone — see testosterone and bone density.
- Vascular function. Endothelial signalling and nitric oxide availability, which links to both cardiovascular health and erectile function.
- Brain. Cognition, mood regulation and neuroprotection; estradiol receptors are widely distributed in male brain tissue.
- Joints and connective tissue. The reason joint pain is such a reliable early complaint when estradiol is crushed.
- Lipids, libido and erectile function. A favourable influence on the HDL and LDL picture, and a genuinely required role in sexual function rather than a permissive one.
When the two hormones were separated experimentally in healthy men — axis suppressed, testosterone added back at different doses, with and without aromatase blockade — a large share of the effect on body fat and sexual desire tracked estradiol rather than testosterone (Finkelstein et al., N Engl J Med 2013). That design is what makes the finding hard to argue with: in ordinary physiology the two move together, so observation alone can never separate them.
Why "estrogen is bad" took hold anyway
The belief came from bodybuilding culture, where supraphysiologic androgen use produces supraphysiologic estradiol and visible gynecomastia is a real outcome. In that context aromatase inhibition made sense; the error was importing the practice into replacement-dose therapy, where the situation is not remotely the same. It persists because the symptoms it prevents — water retention, a puffy face, tender nipples — are visible and immediate, while what estradiol protects is invisible and slow. Bone loss does not announce itself. Nobody feels their endothelium. So the trade looks free, and it is not.
What too little estradiol feels like
- Joint pain, sometimes dramatic and often the first thing to appear
- Low libido despite an excellent testosterone number — the finding that gives the game away
- Erectile difficulty with no other explanation
- Brain fog, flat mood, anxiety
- Reduced exercise capacity and poor recovery; occasional hot flushes
- Accelerated bone loss, which produces no symptoms at all until it does
The diagnostic clue is the combination: high testosterone, low libido, sore joints. That pattern is nearly always estradiol, not dose. Low estrogen symptoms in men works through the presentation.
Where the upper threshold actually sits
Genuinely elevated estradiol can produce gynecomastia, water retention, mood change and, at extremes, reduced libido. Those are real. The problem is that the threshold is considerably higher than the internet assumes — mildly elevated estradiol, in the region of 50-60 pg/mL, frequently produces no symptoms at all in a man who otherwise feels well.
The second problem is attribution. Water retention early in therapy is common, usually settles, and is routinely blamed on estradiol when the cause is a dose or injection schedule producing large peaks. Blocking an enzyme is an odd first response to a delivery problem.
Measure it properly or do not measure it
Standard immunoassays were designed for female concentrations and perform poorly at the much lower levels found in men — an unreliable number in exactly the range where the decision is made (Rosner et al., J Clin Endocrinol Metab 2013). The sensitive assay, by mass spectrometry, is the one worth acting on. Timing matters too: on injectable therapy estradiol tracks testosterone, so a peak draw looks alarming and a trough draw looks reassuring from the same man in the same week. Draw at a consistent point, and read it next to the testosterone from the same sample.
The target, and how to reach it without a drug
Most careful clinicians aim for roughly 20-40 pg/mL on a sensitive assay, with some men feeling best somewhat higher, in the 40-55 range. Below about 20 the low-estradiol picture tends to appear. It is a range, not a minimum, and where a man sits inside it is decided by how he feels rather than by how tidy the number looks. Most of the time it is reached by adjusting inputs rather than blocking the enzyme:
- Lower the peak. Smaller, more frequent injections flatten the testosterone curve, and estradiol follows testosterone. This resolves a large share of apparent estradiol problems on its own.
- Reduce the dose. More aromatisation is often the signature of more testosterone than the man needs.
- Reduce body fat. Adipose tissue is a major site of aromatase expression, which is why heavier men convert proportionally more — the body fat estimate is a crude starting point, and this lever keeps paying afterwards.
- Address alcohol, which impairs hepatic clearance of estradiol and worsens the picture from the other end.
Estradiol management on therapy covers the sequence in more detail.
When an aromatase inhibitor is actually the answer
Sometimes it is, and the indications are narrow: estradiol substantially elevated on a sensitive assay with symptoms that track it, developing gynecomastia, or a man in whom the adjustments above have been tried and failed. What is rarely justified is starting one prophylactically in a man with no symptoms and no measurement. The cost of getting it wrong is measurable — in older men, aromatase inhibition raised testosterone and reduced spine bone mineral density at the same time (Burnett-Bowie et al., J Clin Endocrinol Metab 2009). When to use anastrozole, and when not to works through the decision.
The clinical pearl: if a man on testosterone therapy has a superb testosterone level, no libido and aching joints, the answer is almost never more testosterone. Check a sensitive estradiol, and look at what is being done to suppress it before adding anything else.
Bottom line
Estradiol is not a by-product of testosterone in men; it is one of the two hormones the system runs on, made from testosterone by an enzyme distributed through the tissues that need it. It carries most of the sex-hormone workload in bone, contributes to vascular and brain function, and is required for normal libido and erections. Roughly 20-40 pg/mL on a sensitive assay is a target, not a ceiling to undercut. Most estradiol problems on therapy are dose and frequency problems in disguise, better solved by changing delivery than by blocking the enzyme. Where an inhibitor is genuinely indicated it should follow a measurement and a symptom, not a rumour. The 60-second assessment routes the question to a physician who reads estradiol as a target rather than a nuisance.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
